sorafenib

Eisai’s LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea

Tokyo, Septembe 02, 2018: Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the…

6 years ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420